FDA outlines new onshoring incentives and meeting types for generic drug applicants under GDUFA IV

The FDA released its GDUFA IV commitments, indicating that review timelines for generic drug submissions will remain largely consistent through 2032, mirroring the schedule of the previous five years.

At the same time, the agency introduced new incentives aimed at encouraging domestic manufacturing of generic products, seeking to strengthen the U.S. supply chain.

Additionally, the FDA announced the creation of novel meeting formats to facilitate earlier and more frequent interactions between the agency and generic developers, helping to address potential issues sooner.